- active not recruitingPHASE2
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This study is testing a new medicine, bezuclastinib, for people with certain types of mastocytosis (a rare blood disorder). It compares bezuclastinib with a dummy pill (placebo) to see if it safely helps reduce symptoms that aren't well controlled by current treatments.
United States · Australia · Belgium - recruitingTherapeutic confirmatory (Phase III)
A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with Smouldering or Indolent Severe Systemic mastocytosis with handicap, unresponsive to optimal symptomatic treatment
This study tests a tablet called masitinib for adults with severe systemic mastocytosis. This rare condition causes immune cells to build up, leading to difficult daily symptoms. Researchers want to find out if masitinib can reduce severe symptoms and improve quality of life better than a dummy tablet over 24 weeks.
Poland · France · Spain